Send to

Choose Destination
Am J Hematol. 2017 Jan;92(1):88-93. doi: 10.1002/ajh.24595. Epub 2016 Dec 7.

Management of anemia in patients with congestive heart failure.

Author information

Department of Pathology and Medicine, Stanford University, Stanford, California.
Department of Cardiology, Heart Failure Program, Bellvitge University Hospital and Biomedical Research Institute, Hospitalet de Liobregat, Barcelona, Spain.
Department of Critical Care, Critical Care Division, University Hospital "Virgen delRocío" Avda Manuel Siurot s/n, Seville, Spain.
Institute for Patient Blood Management and Bloodless Medicine and Surgery, Englewood Hospital and Medical Center, Englewood, New Jersey.
Department of Pharmacy, ASHP Pharmacy Residency Program, Investigation Drug Services, Clinical Coordinator for Pharmacy and Therapeutics/Oncology Services, Englewood, New Jersey.
Department of Medicine, Penn Hematology/Oncology Abramson Cancer Center, Pennsylvania Hospital, Philadelphia, Pennsylvania.
Department of Anesthesiology, Englewood Hospital and Medical Center, Englewood, New Jersey.
Department of Hospital Medicine, Temple University School of Medicine, Representing Society of Hospital Medicine, Philadelphia, Pennsylvania.
Department of Anaesthesiology and Reanimation, Hospital Universitaridel Mar, Barcelona, Spain.
Perioperative Medicine Research Group, Hospital del Mar Medical Research Institute. IMIM Coordination of Anemia Working Group España, Spain.
Senior medical director, Accumen LLC, San Diego, California.
Medicine and Surgery, Icahn School of Medicine, New York, New York.
Department of Anesthesiology, Critical Care, Pain and Hyperbaric medicine, Englewood Hospital and Medical Center, TeamHealth Research Institute, Englewood, New Jersey.


Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. Am. J. Hematol. 92:88-93, 2017.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center